MEDGENERA
  • Sections
    • NEWLY PUBLISHED
    • News from Asia-pacific
    • News from Europe
    • News from USA
    • MEDGENERA ORIGINAL
    • ASSESSMENT
    • MARKET INSIGHTS
    • DRUG TRIAL
    • PROGRESSIVE REVIEW
    • APPS & IMPLANTS
  • About us
  • Plans
  • Education
  • Get Online Training
  • Login
  • Webinar
0
  • Login
  • Get 1-Free month
  • Online Course
  • About us
  • BIORISE
  • Plans
  • BUSINESS
  • CAREER
  • HEALTHCARE & MEDICINE
  • IN-DEPTH STORIES
  • KNOWLEDGE CENTRE
  • MEDGENERA EXCLUSIVE
  • NEWLY PUBLISHED
  • News from Asia-pacific
  • News from Europe
  • News from USA
  • RESOURCE CENTRES
  • TECHNOLOGY

Author: admin

Proportion
adminApril 24, 2018

Updated: FDA Declines Pfizer’s ‘Herceptin-Equivalent’ Biosimilar Approval, Needs More Info

USFDA declined the approval of Pfizer’s Herceptin biosimilar for breast cancer treatment. Pfizer’s biosimilar-PF-05280014 has shown equivalence in the objective response rate with Herceptin in HER2-positive metastatic breast cancer patients in clinical studies.

Proportion
adminFebruary 14, 2018

Roche’s Blockbuster Drug Rituxan Prepares for New Rare Disease Treatment

Roche’s top-selling rheumatoid arthritis drug, Rituxan® (rituximab) received US FDA Priority Review status for the treatment of pemphigus vulgaris (PV), ...

Proportion
adminFebruary 12, 2018

HealthifyMe Raises $12 M in Series B Round

HealthifyMe New Funding Bangalore-based digital health and fitness startup, HealthifyMe has raised $12 million in a Series B funding round ...

Privacy Policy Terms Payment Policy Education Contact Us About us